<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905007</url>
  </required_header>
  <id_info>
    <org_study_id>CUH-09-087</org_study_id>
    <nct_id>NCT01905007</nct_id>
  </id_info>
  <brief_title>Study of Defibrillation Testing In Patients Undergoing Initial ICD Implantation</brief_title>
  <acronym>TNT-ICD</acronym>
  <official_title>&quot;Test-No Test&quot; Implantable Cardioverter Defibrillator Pilot Study (TNT-ICD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cooper Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cooper Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the composite outcome of total mortality
      and operative complications in patients who do not undergo defibrillation testing to those
      who do undergo defibrillation testing at the time of initial ICD implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Implantable cardioverter-defibrillators (ICDs) are the most effective treatment for the
      primary and secondary prevention of sudden cardiac death (SCD). At the time of ICD
      implantation, ventricular fibrillation (VF) is typically induced to demonstrate effective
      arrhythmia termination by the implanted device. Although defibrillation threshold (DFT)
      testing with induction of VF at time of ICD insertion is currently considered the &quot;standard
      of care,&quot; and instructions for usage of devices approved by the Food and Drug Administration
      (FDA) include labeling with DFT testing, the value of defibrillation testing with modern-day
      devices has been questioned. Defibrillation testing can be associated with serious
      complications and may add to the cost of the procedure.

      It is hypothesized that patients who do not undergo defibrillation testing will have outcomes
      similar to those who do undergo defibrillation testing at the time of initial implantation.
      This pilot study is being performed to determine the feasibility of performing a larger,
      multi-center clinical trial with longer follow-up to investigate whether or not
      defibrillation testing will have any impact on overall mortality, implant complications, or
      long-term first shock efficacy during clinical follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite all-cause mortality and operative complications</measure>
    <time_frame>Procedure-related complications will be defined as those occurring within 90 days post-implantation and mortality will be measured at 2 year follow-up</time_frame>
    <description>The composite endpoint of implant complications and mortality rates will be compared in the DFT vs. no DFT groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1st shock efficacy for clinical occurrence of ventricular tachycardia (VT)/VF</measure>
    <time_frame>2 years</time_frame>
    <description>The efficacy of 1st shock therapy for VT/VF will be compared between the DFT and no DFT groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ventricular Arrhythmias</condition>
  <arm_group>
    <arm_group_label>Defibrillation testing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Defibrillation testing at initial ICD implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No defibrillation testing</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No defibrillation testing at initial ICD implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Defibrillation testing</intervention_name>
    <description>Defibrillation testing at initial ICD implantation</description>
    <arm_group_label>Defibrillation testing</arm_group_label>
    <other_name>Medtronic implantable cardioverter defibrillator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Initial ICD implantation (single, dual, or CRT) for a standard Class I or Class II
             indication according to the ACC/AHA/HRS practice guidelines

          -  Anticipated life expectancy &gt;6 months

        Exclusion Criteria:

          -  Contraindications to defibrillation testing as determined by the managing physician*

          -  ICD replacement implants

          -  Right-sided pectoral implants

          -  Abdominal implants

          -  Chronic oral amiodarone therapy (for &gt;6 weeks and continued need for amiodarone)

          -  Inability to give informed consent

               -  Contraindications to defibrillation testing include the following: hemodynamic
                  instability, LA thrombus, atrial fibrillation without adequate anticoagulation,
                  LV thrombus, recent CVA or TIA, severe unrevascularized coronary artery disease
                  or unstable angina, severe aortic stenosis, inotropic dependence, patient
                  refusal, other patient-specific medical conditions that are deemed as
                  contraindications, as determined by the implanting physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea M. Russo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cooper Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea M. Russo, MD</last_name>
    <phone>856-968-7096</phone>
    <email>russo-andrea@cooperhealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Field</last_name>
    <phone>856-669-8847</phone>
    <email>field-julie@cooperhealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea M. Russo, M.D.</last_name>
      <phone>856-968-7096</phone>
    </contact>
    <contact_backup>
      <last_name>Julie Field</last_name>
      <phone>856-669-8847</phone>
      <email>Field-Julie@cooperhealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea M. Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Andriulli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Ortman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudine Pasquarello, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanne Poole, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jeanne Poole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, Dixit S, Verdino RJ, Nayak HM, Callans DJ, Patel V, Marchlinski FE. Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm. 2005 May;2(5):456-61.</citation>
    <PMID>15840466</PMID>
  </reference>
  <reference>
    <citation>Swerdlow CD, Russo AM, Degroot PJ. The dilemma of ICD implant testing. Pacing Clin Electrophysiol. 2007 May;30(5):675-700. Review.</citation>
    <PMID>17461879</PMID>
  </reference>
  <reference>
    <citation>Mainigi SK, Cooper JM, Russo AM, Nayak HM, Lin D, Dixit S, Gerstenfeld EP, Hsia HH, Callans DJ, Marchlinski FE, Verdino RJ. Elevated defibrillation thresholds in patients undergoing biventricular defibrillator implantation: incidence and predictors. Heart Rhythm. 2006 Sep;3(9):1010-6. Epub 2006 Jun 15.</citation>
    <PMID>16945792</PMID>
  </reference>
  <reference>
    <citation>Blatt JA, Poole JE, Johnson GW, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Anderson J, Chung K, Wong WS, Mark DB, Lee KL, Bardy GH; SCD-HeFT Investigators. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol. 2008 Aug 12;52(7):551-6. doi: 10.1016/j.jacc.2008.04.051.</citation>
    <PMID>18687249</PMID>
  </reference>
  <reference>
    <citation>Birnie D, Tung S, Simpson C, Crystal E, Exner D, Ayala Paredes FA, Krahn A, Parkash R, Khaykin Y, Philippon F, Guerra P, Kimber S, Cameron D, Healey JS. Complications associated with defibrillation threshold testing: the Canadian experience. Heart Rhythm. 2008 Mar;5(3):387-90. doi: 10.1016/j.hrthm.2007.11.018. Epub 2007 Nov 28.</citation>
    <PMID>18243813</PMID>
  </reference>
  <reference>
    <citation>Pires LA, Johnson KM. Intraoperative testing of the implantable cardioverter-defibrillator: how much is enough? J Cardiovasc Electrophysiol. 2006 Feb;17(2):140-5.</citation>
    <PMID>16533250</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cooper Health System</investigator_affiliation>
    <investigator_full_name>Andrea M. Russo, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Director of Electrophysiology &amp; Arrhythmia Services</investigator_title>
  </responsible_party>
  <keyword>Implantable cardioverter defibrillator</keyword>
  <keyword>Defibrillation threshold testing</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

